QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,106 signal articles · 511 in last 24h · 103,813 total before filter · latest 1h ago
511last 24h
2486last 7d
473● bullish (7d)
254● bearish (7d)
197publishers
AllMacro225Earnings1487M&A143Regulatory15Product5Analyst29
Sentiment:bullishneutralbearishshow all (incl. clickbait)
Qnity Electronics Q2 Earnings Call Highlights
MarketBeat7h agoneutral
Qnity Electronics Q2 Earnings Call Highlights

Qnity Electronics (NYSE:Q) reported second-quarter results that exceeded its expectations, driven by demand tied to artificial intelligence, high-performance computing, advanced connectivity and semiconductor manufacturing. The company raised its full-year outlook after posting 22% year-over-year or

Pinnacle West Capital Q2 Earnings Call Highlights
MarketBeat7h agoneutral
Pinnacle West Capital Q2 Earnings Call Highlights

Pinnacle West Capital (NYSE:PNW) reported second-quarter 2026 earnings of $1.43 per share, down $0.15 from the same period a year earlier, as higher interest expense, depreciation and amortization, and lower transmission revenue more than offset strong weather-driven demand and customer growth. Chi

Pinterest Q2 Earnings Call Highlights
MarketBeat7h agoneutral
Pinterest Q2 Earnings Call Highlights

Pinterest (NYSE:PINS) reported second-quarter revenue of $1.18 billion, up 18% year over year, as the company cited continued user growth, advertising-platform improvements and stronger sales execution in its U.S. and Canada business. The company ended June with 640 million monthly active users, up

Pfizer Q2 Earnings Call Highlights
MarketBeat7h agoneutral
Pfizer Q2 Earnings Call Highlights

Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o

Kraft Heinz Q2 Earnings Call Highlights
MarketBeat7h agoneutral
Kraft Heinz Q2 Earnings Call Highlights

Kraft Heinz (NASDAQ:KHC) said second-quarter results came in ahead of its expectations, prompting the food company to raise its full-year outlook for organic net sales while increasing planned 2026 investments by $100 million to approximately $700 million. Chief Executive Officer Steve Cahillane sa

Clear Secure shares climb after earnings beat and stronger outlook
InvestorsHub7h agobullish
Clear Secure shares climb after earnings beat and stronger outlook

Clear Secure (NYSE:YOU) shares rose more than 6% in pre-market trading on Wednesday after the identity technology company reported second-quarter results that topped Wall Street expectations and issued stronger guidance for the months ahead. The company posted adjusted earnings of $0.

CVS Stock Rises Near Buy Point On Hearty Earnings Checkup
Investor's Business Daily7h agobullish
CVS Stock Rises Near Buy Point On Hearty Earnings Checkup

CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.

Investing.com7h agobullish
Shopify soars on strong revenue beat, robust guidance

Investing.com -- Shopify Inc. (NASDAQ: SHOP) reported second-quarter results that exceeded analyst expectations on both revenue and earnings, sending shares up 26% premarket as the company delivered accelerating growth across key metrics.

Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly Doubles
Barrons.com7h agoneutral
Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly Doubles

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.